A biotechnology company credited as a pioneer in RNA medicines.
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Ionis Pharmaceuticals, Inc..
The 2 sources with the most insights about Ionis Pharmaceuticals, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker said he did not know the stock well; no investment view was provided.
Credited for its decades of foundational work that led to the success of RNA therapeutics, now considered a 'de-risked modality' and a 'mature platform'.
The speaker said he did not know the stock well; no investment view was provided.
Credited for its decades of foundational work that led to the success of RNA therapeutics, now considered a 'de-risked modality' and a 'mature platform'.
Other assets that creators frequently mention in the same content as Ionis Pharmaceuticals, Inc..
The most active sources covering Ionis Pharmaceuticals, Inc. (IONS) on Kazuha are @realmartinshkreli, Andreessen Horowitz. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Ionis Pharmaceuticals, Inc. (IONS) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Ionis Pharmaceuticals, Inc. (IONS) most frequently also discuss PLTR, RGTI, SPX, IONQ, IOVA. See the "Discussed alongside" section above for full asset pages.